Wealthquest Corp Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Wealthquest Corp purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 36,587 shares of the company's stock, valued at approximately $1,037,000.

Several other hedge funds have also made changes to their positions in the business. Allworth Financial LP raised its holdings in Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares in the last quarter. Howard Capital Management Inc. raised its holdings in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after acquiring an additional 297 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after acquiring an additional 345 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after acquiring an additional 356 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research analyst reports. Barclays cut their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada lowered their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. UBS Group lowered their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley decreased their target price on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Finally, Evercore ISI cut their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus price target of $46.61.

Moderna Trading Up 2.5%

MRNA traded up $0.68 during midday trading on Thursday, hitting $27.54. The company's stock had a trading volume of 9,262,694 shares, compared to its average volume of 8,535,028. The firm has a market cap of $10.65 billion, a P/E ratio of -3.15 and a beta of 1.86. The firm has a 50-day moving average price of $26.30 and a two-hundred day moving average price of $32.10. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. Moderna's quarterly revenue was down 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.07) EPS. On average, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.